Deus Technologies got the nod from the FDA to begin selling its RapidScreen RS-2000 to assist in the detection of early-stage lung cancer. The computer-assisted detection system digitizes and analyzes chest radiographs to identify regions of interest
Deus Technologies got the nod from the FDA to begin selling its RapidScreen RS-2000 to assist in the detection of early-stage lung cancer. The computer-assisted detection system digitizes and analyzes chest radiographs to identify regions of interest that may have features associated with early-stage lung cancer. The system uses image enhancement and pattern recognition techniques to locate suspicious areas that may warrant a second review by a radiologist. Deus developed the software using thousands of existing chest images as training data sets. The software contains elements of artificial neural networks and fuzzy logic technology.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.